World
FDA rejects Capricor Duchenne therapy, a decision that was a long The FDA said it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.
The FDA said it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.

FDA rejects Capricor Duchenne therapy, a decision that was a long The FDA said it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics. The FDA said it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.
Continue reading
Latest →Corrections, sourcing and article labels are part of the publication record. See our editorial standards.
